https://imedsciences.com/ editor_ijims@hotmail.com
ISSN: 2394-4137 (E) 2394-6318 (P)

IJIMS.2016.155

Type of Article: Original Research

Volume 3; Issue 11: November 2016

Page No.: 449-453

DOI: 10.16965/ijims.2016.155

Effect of Metformin on Lipid profile of type II Diabetes

Sumanth Garimella 1, V Seshayamma 2, Hari Jagannadha Rao 3, Siva Kumar 4, Uday Kumar 5, Shaik Hussain Saheb *6.

1 Post Graduate, Department of Pharmacology, Alluri SItharama Raju Academy of Medical Sciences, Eluru, Andhra Pradesh, India.

2 Professor & HOD, Department of Pharmacology, Alluri SItharama Raju Academy of Medical Sciences, Eluru, Andhra Pradesh, India.

3 Professor, Department of Pharmacology, Alluri SItharama Raju Academy of Medical Sciences, Eluru, Andhra Pradesh, India.

4 Associate Professor, Department of Pharmacology, Alluri SItharama Raju Academy of Medical Sciences, Eluru, Andhra Pradesh, India.

5 Assistant Professor, Department of Pharmacology, Alluri SItharama Raju Academy of Medical Sciences, Eluru, Andhra Pradesh 534005.

6 Assistant Professor of Anatomy, JJM Medical College, Davange, Karnataka, India.

CORRESPONDING AUTHOR ADDRESS:

Shaik Hussain Saheb, Assistant Professor of Anatomy, JJM Medical College, Davangere -577004, Karnataka, India. Mobile – +91-9242056660.

E-Mail: anatomyshs@gmail.com

ABSTRACT

Introduction: Insulin resistance and type 2 diabetes are associated with a clustering of interrelated plasma lipid and lipoprotein abnormalities, which include reduced HDL cholesterol, increased levels of LDL, TGs, Total cholesterol and VLDL. Each of these dyslipidaemic features is associated with an increased risk of cardiovascular disease. Metformin is used with a proper diet and exercise program and possibly with other medications to control high blood sugar. It is used in patients with type 2 diabetes. Controlling high blood sugar helps prevent kidney damage, blindness, nerve problems, loss of limbs, and sexual function problems. Proper control of diabetes may also lessen your risk of a heart attack or stroke. Metformin works by helping to restore your body’s proper response to the insulin you naturally produce. It also decreases the amount of sugar that your liver makes and that intestines absorb.

Material and Methods: 200 subjects were selected from diabetic type II patients who are on treatment of only metformin(1500mg/daily). The parameters were performed after 3 months of treatment. FBS, Insulin, TC, TGs, HDL-C, LDL-C and VLDL –C were measured.

Results: The results of this study showed improved levels of FBS. The total cholesterol, triglycerides, LDL-C and VLDL-C were reduced significantly(P<0.05). the HDL-C levels were increased significantly after treatment with metformin.

Conclusion: The results were clearly indicated that beneficial effect of metformin on lipid profile of type II diabetes. Hence concluded that metformin having the ability to correct dyslipidaemia in type II diabetic patients.

Key words: Type II Diabetes, Metformin, Dyslipidaemia, Lipid profile.

REFERENCES

  1. Singh G, Kumar A.K. A Study of Lipid Profile in Type 2 Diabetic Punjabi population. Journal of Exercise Science and Physiotherapy, Vol. 8, No. 1: 7-10, 201.
  2. Mooradian AD. Dyslipidemia in type 2 diabetes mellitus. Nat Clin Pract Endocrinol Metab.2009 Mar;5(3):150-9.
  3. Steiner G. A new perspective in the treatment of dyslipidemia : can fenofibrate offer unique benefits in the treatment of type 2 diabetes mellitus?. Treat Endocrinol.2005;4(5):311-7.
  4. Frayn  KN Insulin resistance and lipid metabolism. Curr Opin Lipidol.1993;4197- 204.
  5. Kreisberg  RA Diabetic dyslipidemia. Am J Cardiol.1998;8267U- 73U.
  6. American Diabetes Association, Clinical practice recommendations 1998: management of dyslipidemia in adults with diabetes [position statement]. Diabetes Care.1998;21 (suppl) S36- S39.
  7. Pyorala  KLaakso  MUusitupa  M Diabetes and atherosclerosis: an epidemiologic view. Diabetes Metab Res Rev.1987;3463- 524.
  8. Grundy  SMBenjamin  IJBurke  GL  et al.  Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. 1999;1001134- 1146.
  9. Godarzi MO, Brier-Ash M: Metformin revisited: re-evaluation of its properties and role in the pharmacopoeia of modern antidiabetic agents. Diabetes Obes Metab. 2005, 5: 654-665.
  10. Shaw RJ, Lamia KA, Vasquez D: The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science. 2005, 310: 1642-1646. 10.1126/science.1120781.
  11. El-Mir MY, Nogueira V, Fontaine E: Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I. J Biol Chem. 2000, 275: 223-228. 10.1074/jbc.275.1.223.
  12. Wild S, Roglic G, Green A, Sicree R, King H: Global prevalence of diabetes. Estimates for the year 2000 and projections for 2030. Diabetes Care. 2004, 27: 1047-1053. 10.2337/diacare.27.5.1047.
  13. Guillies C, Abram KR, Lambert PC, Cooper NJ, Sutton AJ: Pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance: systematic review and meta-analysis. BMJ. 2007, 334: 299-10.1136/bmj.39063.689375.55.
  14. Petersen J, Mc Guire D: Impaired glucose tolerance and impaired fasting glucose – a review of diagnosis, clinical implications and management. Diabetes Vasc Dis Res. 2005, 2 (1): 9-15. 10.3132/dvdr.2005.007.
  15. Lilian Beatriz,  Aguayo Rojas, Marilia Brito Gomes. Metformin: an old but still the best treatment for type 2 diabetes Diabetology & Metabolic Syndrome20135:6.
  16. Wulffele MG, Kooy A, de Zeeuw D, Stehouwer CD, Gansevoort RT. The effect of metformin on blood pressure, plasma cholesterol and triglycerides in type 2 diabetes mellitus: a systematic review. J Int Med 2004;256:1-14.
  17. Manzella D, Grella R, Esposito K, Giugliano D, Barbagallo M, Paliosso G. Blood pressure and cardiac autonomic nervous system in obese type 2 diabetic patients: effect of metformin administration. Am J Hypert 2004;17:223-227.
  18. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention of metformin. N Engl J Med 2002;346:393-403.
  19. UK Prospective Diabetes study Group. Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-865.
  20. Gargiulo P, Caccese D, Pignatelli P, Brufani C, De Vito F, Marino R, et al. Metformin decreases platelet superoxide anion production in diabetic patients. Diabetes Metab Res Rev 2002;18:156159.
  21. Beisswenger P, Ruggiero-Lopez, D. Metformin inhibition of glycation processes. Diabetes Metab 2003;29:6S95-6S103.
  22. Mamputu JC, Wiernsperger NF, Reiner G. Antiatherogenic properties of metformin: the experimental evidence. Diabetes Metab 2003;29:6S71-6S76.
  23. Weitgasser R. Effects of glimepiride on HbA1c and body weight in Type 2 diabetes: results of a 1.5-year follow-up study, Diabetes research and clinical practice. 2003;61:13-19.
  24. Inglea P and Taleleb G. Effects of metformin in combination with glimepiride on HbA1c and body mass index inIndian patients with type 2 diabetes mellitus, Journal of Pharmacy Research. 2010; 3(9): 2177-2179.
  25. Min W. Effect of short-term intensive therapy with glimepiride and metformin in newly diagnosed type 2 diabetic patients J. South Med Univ. 2011;31:564-566.
  26. Charpentier G, Fleury F, Kabir M, Vaur L and Halimi S., Improved glycaemic control by addition of glimepiride to metformin monotherapy in Type 2 diabetic patients, Diabetic Medicine. 2001;18:828-834.
  27. Moses R. Effect of repaglinide addition to metformin monotherapy onglycemic control in patients with type 2 diabetes. Diabetes Care. 1999;22:119-124.
  28. Ramachandran A, Snehalatha C, Salini J and Vijay V. Use of Glimepiride and Insulin Sensitizers in the Treatment of Type 2 Diabetes. A Study in Indians, JAPI. 2004;52:459-463.
  29. Haupt E, Knick B, Koschinsky T, Liebermeister H, Schneider J and Hirche H. Oral antidiabetic combination therapy with sulphonylureas and metformin. Diabetes Metab. 1991;17:224-31.
  30. Riddle M. Combining sulfonylureas and other oral agents. Am J Med. 2000;108(Suppl) 6a:15S-22S.
  31. Salpeter SR, Greyber E, Pasternak GA and Salpeter EE. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus: systematic review and meta-analysis. Arch Intern Med. 2003;163:2594.
  32. Kim HJ. Effects of rosiglitazone and metformin on inflammatory markers and adipokines: decrease in interleukin-18 is an independent factor for the improvement of homeostasis model assessment-beta in type 2 diabetes mellitus,Clin. Endocrinol. (Oxf.) 2007;66(2):282-9.
  33. Riccio A, Del Prato S, De Kreutzenberg SV and Tiengo A. Glucose and lipid metabolism in non-insulin dependent diabetes: effect of metformin. Diabetes Metab. 1991;17:180–184.
Download Full Text TOC